Dr Tatyana Shelkovnikova
Group Leader

I have been involved in biomedical research since 2008. My PhD project was aimed at development and validation of in vitro and in vivo models for testing the effects of neuroprotective compounds. In 2012, after completion of PhD studies and a short-term EMBO fellowship, I joined Prof Buchman’s laboratory at Cardiff University as a postdoctoral researcher. Between 2012 and 2015, I worked on the molecular mechanisms of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Wishing to focus on the previously overlooked link between a nuclear RNA granule, the paraspeckle, and ALS pathogenesis, in 2015 I obtained dedicated funding from the Medical Research Foundation (3-year fellowship). In September 2018, I started as a MND Association Senior Non-Clinical Fellow and independent group leader at the Cardiff University Medicines Discovery Institute. In September 2021, I moved to the Sheffield Institute for Translational Neuroscience (SITraN) and in August 2022, started as a UKRI Future Leaders Fellow. The lab has been fully operational since Nov 2022, when the first lab members were recruited. The lab is currently supported by MRC, MND Association, BBSRC and MND Scotland.


  • European Network for the Cure of ALS (ENCALS) Young Investigator Award 2020.
  • Featured in the Lifeline section of the Lancet Neurology journal.

Selected talks

  • SInFoNiA institute seminar (2022, Sheffield, UK)
  • RNA UK (2022, Windermere, UK).
  • 30th International Symposium on ALS/MND (2019, Perth, Australia). Given by lab member
  • 29th International Symposium on ALS/MND (2018, Glasgow, UK).
  • 2nd International Symposium on Stress-Associated RNA Granules in Human Disease and Viral Infection (2017, Heidelberg, Germany).
  • Gordon Research Seminar ‘Neurobiology of Brain Disorders’ (2014, Girona, Spain).
  • ‘RNA metabolism: changing paradigms in neurodegeneration’ meeting (2014, Trieste, Italy).
  • 7th Mammalian Genes, Development and Disease Meeting (2013, Cardiff, UK).
  • 5th Conference on Advances in molecular mechanisms underlying neurological disorders (ESN/ Biochemical Society meeting; 2013, Bath, UK). Plenary communication
  • European Network for the Cure of ALS (ENCALS) Meeting 2013 (2013, Sheffield, UK).
  • Invited session leader at GRS ‘Neurobiology of Brain Disorders’ (2016, Girona, Spain).

Departmental seminar speaker

  • University of Sheffield, SITRaN neuroscience seminar series (Feb, 26, 2021 – virtual seminar)
  • Manchester University, School of Biological Sciences (Dec 7, 2020 – virtual seminar)
  • Cardiff University School of Dentistry (Feb 12, 2020)
  • University College London Institute of Neurology (Jun 11, 2019)
  • Engelhardt Institute of Molecular Biology (Feb 12, 2019, Moscow, Russia)
  • Department of Clinical Neurosciences, Palermo University (Dec 15, 2018, Palermo, Italy)
  • School of Molecular Sciences, University of Western Australia (Nov 29, 2017, Australia)
  • CHU-Lille Alzheimer&Tauopathies, Inserm (Sept 14, 2017, Lille, France)
  • Graduate School of Medicine, University of Tokyo (Nov 11, 2015, Tokyo, Japan)


Grants: MRC; BBSRC; MND Association; Templeton Foundation; Strasbourg Institute for Advanced Studies (USIAS); Worldwide Cancer Research; French National Research Agency (ANR); Research Foundation Flanders’ (FWO); Israel Science Foundation; French Research Association on ALS; European Science Foundation.

Papers: reviewed for >30 journals, including Nat Neurosci, Nat Commun; Sci Transl Med; Trends Genet; J Cell Biol, EMBO Rep, Cell Rep, Ann Neurol, Mol Neurodegener; >40 papers, for full list– see Publons: https://publons.com/researcher/1517684/tatyana-shelkovnikova/

PhD viva examiner

  • University College London / Crick Institute, London, UK (2021)
  • King’s College London (2021-22)